News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Daily News COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK Michael O'Riordan September 15, 2022
News Daily News Acute MI, Stroke Risks Rise in the Months After Gout Flares Todd Neale August 02, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News CV Risk Factor Control Cuts Post-op Nursing Home Transfer for Black Americans Yael L. Maxwell July 22, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits Yael L. Maxwell June 23, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News EuroPCR 2022 Registry Data Hint at MACE Benefit With Renal Denervation Michael O'Riordan May 17, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis Michael O'Riordan February 18, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022